CD300LB

Across TCGA pan-cancer cohorts, CD300LB Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD300LB data layer compared with 25 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CD300LB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD300LB expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, SCLC, and UCEC are the cancer types where CD300LB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.133	0.720	<.001	42	view →
SCLC	OS	Median	II,III,IV	0.055	0.702	<.001	30	view →
UCEC	DFS	Median	All	1.000	0.629	.024	16	view →
LIHC	OS	Median	II,III,IV	0.255	0.768	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD300LB–BLCA (OS)

Open the BLCA breakdown →